XBRANE Stock Overview
A biotechnology company, engages in the development, manufacture, and sale of biosimilars. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Xbrane Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.20 |
| 52 Week High | SEK 0.37 |
| 52 Week Low | SEK 0.13 |
| Beta | 0.98 |
| 1 Month Change | 40.06% |
| 3 Month Change | 17.09% |
| 1 Year Change | -40.61% |
| 3 Year Change | -99.79% |
| 5 Year Change | -99.45% |
| Change since IPO | -99.43% |
Recent News & Updates
Analysts Are Betting On Xbrane Biopharma AB (publ) (STO:XBRANE) With A Big Upgrade This Week
Apr 04
Investors Still Aren't Entirely Convinced By Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Despite 33% Price Jump
Mar 21Recent updates
Analysts Are Betting On Xbrane Biopharma AB (publ) (STO:XBRANE) With A Big Upgrade This Week
Apr 04Investors Still Aren't Entirely Convinced By Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Despite 33% Price Jump
Mar 21Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely
Sep 30Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower
Aug 05Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost
Jun 21Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?
Jun 04We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully
Nov 05Shareholder Returns
| XBRANE | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 10.8% | 6.6% | 9.2% |
| 1Y | -40.6% | -4.8% | -4.5% |
Return vs Industry: XBRANE underperformed the Swedish Biotechs industry which returned -4.6% over the past year.
Return vs Market: XBRANE underperformed the Swedish Market which returned -3.4% over the past year.
Price Volatility
| XBRANE volatility | |
|---|---|
| XBRANE Average Weekly Movement | 16.7% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in SE Market | 13.9% |
| 10% least volatile stocks in SE Market | 4.2% |
Stable Share Price: XBRANE's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: XBRANE's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 65 | Martin Amark | www.xbrane.com |
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis, Crohn’s disease, and axial spondylitis; Xdivane, a nivolumab biosimilar candidate, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma.
Xbrane Biopharma AB (publ) Fundamentals Summary
| XBRANE fundamental statistics | |
|---|---|
| Market cap | SEK 310.73m |
| Earnings (TTM) | -SEK 265.02m |
| Revenue (TTM) | SEK 198.72m |
1.6x
P/S Ratio-1.2x
P/E RatioIs XBRANE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XBRANE income statement (TTM) | |
|---|---|
| Revenue | SEK 198.72m |
| Cost of Revenue | SEK 18.23m |
| Gross Profit | SEK 180.50m |
| Other Expenses | SEK 445.52m |
| Earnings | -SEK 265.02m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 90.83% |
| Net Profit Margin | -133.36% |
| Debt/Equity Ratio | 71.4% |
How did XBRANE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/16 07:58 |
| End of Day Share Price | 2025/04/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xbrane Biopharma AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Savin | Edison Investment Research |
| Hans Mähler | Nordea Markets |
| null null | Nordea Markets |